Intravesical pembrolizumab - Lipella Pharmaceuticals
Alternative Names: LP-50Latest Information Update: 20 Jul 2024
At a glance
- Originator Lipella Pharmaceuticals
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
- Mechanism of Action Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Bladder cancer
Most Recent Events
- 31 May 2024 Pharmacodynamics data from a preclinical study presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 05 Apr 2024 Preclinical trials in Bladder cancer in USA (Intravesicular) prior to April 2024
- 11 Nov 2022 Lipella Pharmaceuticals files for patent protection with US PTO for intravesical delivery of hydrophilic therapeutic agents using liposomes